Equities analysts expect Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) to announce sales of $31.93 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kiniksa Pharmaceuticals’ earnings, with the highest sales estimate coming in at $42.89 million and the lowest estimate coming in at $20.96 million. The company is expected to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full-year sales of $119.15 million for the current financial year, with estimates ranging from $114.54 million to $123.76 million. For the next financial year, analysts anticipate that the business will post sales of $211.82 million, with estimates ranging from $199.05 million to $224.59 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Rating) last issued its quarterly earnings results on Tuesday, February 22nd. The company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.09). The company had revenue of $18.75 million during the quarter, compared to analysts’ expectations of $16.32 million.
Several institutional investors have recently made changes to their positions in KNSA. Walleye Capital LLC bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter worth about $981,000. BlackRock Inc. lifted its position in shares of Kiniksa Pharmaceuticals by 11.7% in the fourth quarter. BlackRock Inc. now owns 3,483,852 shares of the company’s stock valued at $41,007,000 after buying an additional 363,530 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Kiniksa Pharmaceuticals by 18.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 579,217 shares of the company’s stock valued at $6,817,000 after buying an additional 89,644 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Kiniksa Pharmaceuticals by 1.6% during the fourth quarter. Deutsche Bank AG now owns 80,367 shares of the company’s stock worth $946,000 after purchasing an additional 1,255 shares during the period. Finally, California State Teachers Retirement System increased its stake in shares of Kiniksa Pharmaceuticals by 2.8% during the fourth quarter. California State Teachers Retirement System now owns 36,395 shares of the company’s stock worth $428,000 after purchasing an additional 989 shares during the period. Institutional investors own 43.01% of the company’s stock.
NASDAQ KNSA traded up $0.13 during trading on Wednesday, reaching $11.23. 123,255 shares of the company’s stock were exchanged, compared to its average volume of 325,620. Kiniksa Pharmaceuticals has a fifty-two week low of $9.05 and a fifty-two week high of $17.46. The company’s fifty day simple moving average is $10.46 and its 200-day simple moving average is $11.48.
About Kiniksa Pharmaceuticals (Get Rating)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.